SynthesisFuture oncology (London, England)2024
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
Amin Haiderali et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this paperpooled itcites it